<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997022</url>
  </required_header>
  <id_info>
    <org_study_id>AAAD3519</org_study_id>
    <nct_id>NCT00997022</nct_id>
  </id_info>
  <brief_title>Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients</brief_title>
  <official_title>Phase I Open-Label, Dose-Finding Study of BAY 43-9006 (Sorafenib) in High-risk Hepatocellular Cancer Patients After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study of sorafenib in high risk hepatocellular cancer patients after liver&#xD;
      transplantation will study 24 subjects for about 5 years. Each subject will receive sorafenib&#xD;
      for 6 months. Safety and effectiveness on the post transplant, high risk HCC patients will be&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor with effects on tumor proliferation&#xD;
      and angiogenesis. Sorafenib is approved for the treatment of patients with advanced renal&#xD;
      cancer and unresectable hepatocellular carcinoma (HCC). The recommended daily dose of&#xD;
      Sorafenib is 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour&#xD;
      before or 2 hours after a meal). Studies of single-agent sorafenib showed treatment was&#xD;
      well-tolerated with manageable side effects. The results seen with sorafenib in the Phase III&#xD;
      (SHARP) trial suggest that VEGF and RAF kinase inhibition prolong survival in patients with&#xD;
      advanced HCC. It is not known whether a drug which is considered primarily cytostatic will be&#xD;
      effective in preventing cancer recurrences in the setting of minimal residual disease.&#xD;
&#xD;
      This is a phase I, single center, open-label, dose-escalation study to determine the maximum&#xD;
      tolerated dose (MTD) and overall safety profile of daily sorafenib as therapy to prevent HCC&#xD;
      recurrence in liver transplant subjects with high-risk HCC. For each subject, the study will&#xD;
      consist of two phases: a treatment phase and an extension phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of daily sorafenib</measure>
    <time_frame>Every two weeks throughout six cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of disease free survival</measure>
    <time_frame>Every three months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of progression free survival</measure>
    <time_frame>Every three months for 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily sorafenib taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Dose escalation:&#xD;
Dose level 1: 200mg of sorafenib daily&#xD;
Dose level 2: 200mg of sorafenib BID (twice daily)&#xD;
Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)&#xD;
Dose level 4: 400mg BID (twice daily)</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Post liver transplant and have explants with histologically confirmed hepatocellular&#xD;
             carcinoma.&#xD;
&#xD;
          -  No evidence of HCC disease at study entry by imaging&#xD;
&#xD;
          -  Eligible to start 4 weeks post transplant (29 days post transplant) as long as they&#xD;
             are on stable doses of immunosuppressants.&#xD;
&#xD;
          -  &quot;High risk&quot; for recurrence after transplantation&#xD;
&#xD;
          -  Received prior surgical resection, chemoembolization or other local therapy prior to&#xD;
             transplant.&#xD;
&#xD;
          -  Have Child-Pugh Class A or compensated Child-Pugh Class B liver dysfunction at the&#xD;
             start of therapy&#xD;
&#xD;
          -  Have adequate bone marrow, liver and renal function as assessed by the following:&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dl&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3&#xD;
&#xD;
               -  Platelet count ≥ 75,000/mm3&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
               -  ALT and AST ≤ 5 x ULN&#xD;
&#xD;
               -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
               -  Albumin ≥ 2.5 mg/dl&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 14 days prior to the start of treatment&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (barrier method of birth control) prior to study entry and for the duration of study&#xD;
             participation. Men should use adequate birth control for at least three months after&#xD;
             the last administration of sorafenib.&#xD;
&#xD;
          -  Exhibit the ability to understand and willingness to sign a written informed consent&#xD;
             regarding the study and alternative treatments.&#xD;
&#xD;
          -  INR &lt; 1.5 or a PT/PTT within normal limits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac disease: Congestive heart failure &gt; class II NYHA.&#xD;
&#xD;
          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as systolic blood pressure &gt; 150 mmHg or diastolic&#xD;
             pressure &gt; 90 mmHg, despite optimal medical management.&#xD;
&#xD;
          -  Active clinically serious infection &gt; CTCAE Grade 2.&#xD;
&#xD;
          -  Thromboembolic events such as a cerebrovascular accident (including transient ischemic&#xD;
             attacks) within the past 6 months.&#xD;
&#xD;
          -  Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Serious non-healing wound, ulcer, or bone fracture within 4 weeks of first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy within 4 weeks of first dose&#xD;
             of study drug.&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first&#xD;
             study drug.&#xD;
&#xD;
          -  Use of St. John's Wort or rifampin within 4 weeks of first dose of study drug.&#xD;
&#xD;
          -  Known or suspected allergy to sorafenib or any agent given in the course of this&#xD;
             trial.&#xD;
&#xD;
          -  Any condition that impairs patient's ability to swallow whole pills.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding. Breastfeeding should be discontinued if&#xD;
             the patient is to be treated.&#xD;
&#xD;
          -  Prior malignancy treated during the prior 5-years (other than localized non-melanoma&#xD;
             carcinoma of the skin).&#xD;
&#xD;
          -  Any condition or social situation that may limit patient's compliance with the study&#xD;
             regimen&#xD;
&#xD;
          -  Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI&#xD;
             of the brain to exclude brain metastasis prior to enrollment.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection (hepatitis B and hepatitis C&#xD;
             infection will not be exclusion criteria.&#xD;
&#xD;
          -  Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Any malabsorption problem which in the investigator's opinion would prevent adequate&#xD;
             absorption of the sorafenib.&#xD;
&#xD;
          -  On M-Tor inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abby Siegel, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>High-risk Hepatocellular Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

